ストックスクリーナーアプリを入手
3.92
5.54%
-0.23
前日終値:
$4.15
開ける：
$3.65
24時間の取引高:
6.20M
Relative Volume:
156.30
時価総額：
$3.70M
収益：
$129.20K
当期純損益:
$-7.44M
株価収益率:
-0.3503
EPS:
-11.19
ネットキャッシュフロー:
$-8.62M
1週間 パフォーマンス:
+240.87%
1か月 パフォーマンス:
+235.88%
6か月 パフォーマンス:
+124.00%
1年 パフォーマンス:
-44.32%
1日の値動き範囲:
$3.10
$4.14
1週間の範囲:
$1.105
$4.40
52週間の値動き範囲:
$1.08
$10.02
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
名前
Sonnet Biotherapeutics Holdings Inc
セクター
電話
609-375-2227
住所
100 OVERLOOK CENTER, PRINCETON, NJ
SONN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SONN
Sonnet Biotherapeutics Holdings Inc
|
3.92 | 3.70M | 129.20K | -7.44M | -8.62M | -11.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sonnet Biotherapeutics Holdings Inc (SONN) 最新ニュース
Two Sigma Investments LP Invests $28,000 in Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) - Defense World
Reviewing Sonnet BioTherapeutics (NASDAQ:SONN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
sonnet biotherapeutics receives nasdaq delisting notice By Investing.com - Investing.com South Africa
sonnet biotherapeutics receives nasdaq delisting notice - Investing.com
Sonnet BioTherapeutics Faces Nasdaq Non-Compliance Notice - TipRanks
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Price Up 5.3% – What’s Next? - Defense World
SONN stock touches 52-week low at $1.1 amid market challenges - Investing.com Australia
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sonnet BioTherapeutics Holdings, Inc. SEC 10-Q Report - TradingView
Sonnet BioTherapeutics (SONN) Expected to Announce Earnings on Tuesday - Defense World
Sonnet Chief Medical Officer, Richard Kenney, M.D., to - GlobeNewswire
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit - The Globe and Mail
Chanticleer Holdings Little Big Burger Partner and Brand Ambassador Denny Hamlin Wins the Daytona 500 - marketscreener.com
Sonnet Releases Virtual Investor "What This Means" Segment | SONN Stock News - GuruFocus
Sonnet BioTherapeutics Discusses Positive Safety Data for SON-1010 in Virtual Investor Segment - Nasdaq
Sonnet Releases Virtual Investor "What This Means" Segment - GlobeNewswire
Biotech Leader Dr. Pankaj Mohan Honored on NASDAQ After Tragic Crash - newsindiatimes.com
Sonnet BioTherapeutics (NASDAQ:SONN) Receives Buy Rating from Chardan Capital - Defense World
SONN stock touches 52-week low at $1.18 amid market challenges - Investing.com India
Sonnet BioTherapeutics reports positive results from ovarian cancer therapy trial - Yahoo Finance
Sonnet BioTherapeutics advances in cancer trial - Investing.com Australia
Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up - MarketScreener
Sonnet BioTherapeutics advances in cancer trial By Investing.com - Investing.com South Africa
Sonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab combo - TipRanks
Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose - The Manila Times
Sonnet'S Son-1010 Demonstrates A Strong Safety Profile In Combination With Atezolizumab For Treatment Of Platinum-Resistant Ovarian Cancer - MarketScreener
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in - GlobeNewswire
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose - GlobeNewswire
Sonnet BioTherapeutics appoints interim CEO and new president By Investing.com - Investing.com Canada
Sonnet Announces Release of Corporate Update Video - GlobeNewswire
Sonnet BioTherapeutics appoints interim CEO and new president - Investing.com
Sonnet BioTherapeutics Announces New Interim CEO Appointment - TipRanks
Pilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech Company - NewsBreak: Local News & Alerts
Pilot killed in N.J. plane crash was biotech company founder, CEO - NJ.com
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - citybiz
Sonnet BioTherapeutics appoints interim CEO after founder’s death - Investing.com
Sonnet Announces The Passing Of Founder And CEO Pankaj Mohan - marketscreener.com
Chardan Capital Reaffirms Buy Rating for Sonnet BioTherapeutics (NASDAQ:SONN) - Defense World
Sonnet BioTherapeutics’ (SONN) Buy Rating Reaffirmed at Chardan Capital - The AM Reporter
SONN stock touches 52-week low at $1.28 amid market challenges - Investing.com Australia
Sonnet BioTherapeutics Successfully Completes First Safety - GlobeNewswire
Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas - MarketScreener
Sonnet Biotherapeutics Holdings Inc (SONN) 財務データ
収益
当期純利益
現金流量
EPS
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):